| Paroxysmal nocturnal hemoglobinuria
PiaSky vs Fabhalta
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Piasky vs Fabhalta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFabhalta has a higher rate of injection site reactions vs Piasky based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fabhalta but not Piasky, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Piasky
Fabhalta
At A Glance
IV infusion / SC injection
Every 4 weeks (maintenance)
Complement C5 inhibitor
Oral
Twice daily
Factor B inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- Paroxysmal nocturnal hemoglobinuria
- IGA Glomerulonephritis
- Complement 3 Glomerulopathies
Dosing
Paroxysmal nocturnal hemoglobinuria Loading: 1,000 mg (>=40 kg to <100 kg) or 1,500 mg (>=100 kg) IV on Day 1, then 340 mg SUBQ on Days 2, 8, 15, and 22; maintenance 680 mg (>=40 kg to <100 kg) or 1,020 mg (>=100 kg) SUBQ every 4 weeks starting Day 29.
Paroxysmal nocturnal hemoglobinuria, IGA Glomerulonephritis, Complement 3 Glomerulopathies 200 mg orally twice daily without regard to food; swallow capsules whole.
PNH Patients Switching From Anti-C5 Initiate FABHALTA no later than 1 week after last eculizumab dose or no later than 6 weeks after last ravulizumab dose.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- Known serious hypersensitivity reaction to crovalimab or any excipient
- Serious hypersensitivity to iptacopan or any of the excipients
- Unresolved serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type b (contraindicated for initiation)
Adverse Reactions
Most common (>=10%) Infusion-related reaction, respiratory tract infection, viral infection, Type III hypersensitivity reaction, peripheral edema, headache
Serious Epistaxis, pneumonia, infusion-related reaction, pyelonephritis, COVID-19, hypovolemic shock, nasopharyngitis, urinary tract infection
Most common (>=10%) headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, rash
Serious serious infections caused by encapsulated bacteria, hyperlipidemia
Pharmacology
Crovalimab-akkz is a humanized IgG1 monoclonal antibody that binds with high affinity to complement protein C5, inhibiting its cleavage into C5a and C5b and preventing formation of the membrane attack complex (MAC), thereby inhibiting terminal complement-mediated intravascular hemolysis in patients with PNH.
Factor B inhibitor; iptacopan binds to Factor B of the alternative complement pathway, regulating C3 cleavage and inhibiting downstream effectors to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in PNH, and to inhibit complement-driven glomerular injury in IgAN and C3G.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Piasky
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Fabhalta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Piasky
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Fabhalta
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Piasky
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Fabhalta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Immunoglobulin A Nephropathy (IgAN)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PiaskyView full Piasky profile
FabhaltaView full Fabhalta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.